GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 64.7 USD | +1.35% |
|
+0.67% | -20.13% |
Financials (USD)
| Sales 2024 * | 27.59B | Sales 2025 * | 27.99B | Capitalization | 80.61B |
|---|---|---|---|---|---|
| Net income 2024 * | 387M | Net income 2025 * | 6.3B | EV / Sales 2024 * | 3.58 x |
| Net Debt 2024 * | 18.17B | Net Debt 2025 * | 13.18B | EV / Sales 2025 * | 3.35 x |
| P/E ratio 2024 * |
189
x | P/E ratio 2025 * |
12.5
x | Employees | 18,000 |
| Yield 2024 * |
4.79% | Yield 2025 * |
5.08% | Free-Float | 99.89% |
More Fundamentals
* Assessed data
More news
Latest transcript on Gilead Sciences, Inc.
More recommendations
More press releases
More news
| 1 day | +1.33% | ||
| 1 week | +0.67% | ||
| Current month | +0.67% | ||
| 1 month | +0.19% | ||
| 3 months | -13.87% | ||
| 6 months | -18.12% | ||
| Current year | -20.13% |
1 week
63.20
64.92
1 month
62.0768.37
Current year
62.0787.87
1 year
62.0787.87
3 years
57.1789.74
5 years
56.5689.74
10 years
56.56123.37
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 59 | 19-02-28 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 15-12-31 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 20-10-16 |
| Director/Board Member | 71 | 17-12-31 | |
Ted Love
BRD | Director/Board Member | 65 | Jan. 31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 208 M€ | +13.89% | - | |
| 8.10% | 0 M€ | 0.00% | - | |
| 8.06% | 0 M€ | 0.00% | - | |
| 5.23% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 64.7 | +1.33% | 7,412,695 |
| 24-06-06 | 63.85 | -0.05% | 6,087,410 |
| 24-06-05 | 63.88 | -0.44% | 6,145,808 |
| 24-06-04 | 64.16 | +1.15% | 6,593,105 |
| 24-06-03 | 63.43 | -1.31% | 8,560,896 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
2024-06-12
- Goldman Sachs Global Healthcare Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
64.7
USD
Average target price
82.7
USD
Spread / Average Target
+27.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.13% | 80.61B | |
| +45.82% | 765B | |
| -6.16% | 354B | |
| +19.86% | 331B | |
| +9.32% | 299B | |
| +18.45% | 248B | |
| -0.78% | 219B | |
| +11.88% | 216B | |
| +5.90% | 164B | |
| -0.73% | 162B |
- Stock Market
- Equities
- GILD Stock
